Navigation Links
Prostate Oncology Specialists Among First in the Nation to Treat Advanced Prostate Cancer Patients With PROVENGE
Date:10/27/2010

immune system to identify and target prostate cancer cells. Each dose is manufactured specifically for each patient using his immune cells.

The Centers for Medicare and Medicaid Services are currently undergoing a National Coverage Analysis (NCA) regarding autologous cellular immunotherapy treatment of metastatic prostate cancer.  As part of the NCA process, Dr. Scholz will provide an expert opinion on PROVENGE data at the November 17th Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) meeting in Baltimore, MD.

In addition, Dr. Scholz will be giving a presentation on the latest developments in treating advanced prostate cancer, including new immunological approaches such as PROVENGE and effective chemotherapy combinations, at an UsTOO educational session in Fullerton, CA on Thursday, October 28th beginning at 5 p.m. PT.  For press attendance credentials or information on location for patients, please contact Lew Pfeffer at (626) 333-6034.

PROVENGE Safety

PROVENGE is intended solely for autologous use and is not routinely tested for transmissible infectious diseases.

In controlled clinical trials, serious adverse events reported in the PROVENGE group included acute infusion reactions (occurring within 1 day of infusion) and cerebrovascular events.  Severe (Grade 3) acute infusion reactions were reported in 3.5% of patients in the PROVENGE group.  Reactions included chills, fever, fatigue, asthenia, dyspnea, hypoxia, bronchospasm, dizziness, headache, hypertension, muscle ache, nausea, and vomiting. No Grade 4 or 5 acute infusion reactions were reported in patients in the PROVENGE group.

The most common adverse events (incidence >15%) reported in the PROVENGE group are chills, fatigue, fever, back pain, nausea, joint ache, and headache.

Please see full Prescribing Information for PROVENGE at www.provenge.com.

<
'/>"/>

SOURCE Prostate Oncology Specialists, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Reportlinker Adds Prostate Cancer Drug Futures
2. Robotic Prostatectomy Expert Dr. David Samadi, MD Discusses Prostate Cancer Treatment Drug Abiraterone
3. Abiraterone Acetate Significantly Improved Overall Survival for Patients with Metastatic Advanced Prostate Cancer
4. Prostate Cancer Treatment Expert Dr. David Samadi, MD Discusses Study Which Found That Low-Income Men Had High-Risk Prostate Cancer Tumors
5. Phase III Data Showing Improved Survival With Jevtana® (cabazitaxel) Injection in Second-Line Advanced Prostate Cancer Published in The Lancet
6. Surveyed European Oncologists Assign Greater Patient Share to Johnson & Johnsons Abiraterone Compared With Other Emerging Therapies in Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
7. AMS Announces Worldwide Launch of the Revolutionary MoXy™ Liquid Cooled Fiber for Fast, Safe Treatment of Enlarged Prostate
8. With Over 3,000 Robotic Prostatectomy Surgeries to His Credit, Dr. David Samadi, MD Discusses SMART Surgery and How it Improves Sexual and Urinary Function
9. Pfizer Discontinues Phase 3 Trial of SUTENT® in Advanced Castration-Resistant Prostate Cancer
10. Robotic Prostatectomy Expert Dr. David Samadi, MD Introduces His SMART Surgery Website for Prostate Cancer Treatment Education
11. ProstateHealthIndex.org Website Offers Latest on Assessing Prostate Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... /PRNewswire-iReach/ -- CountryFocus: Healthcare, Regulatory and Reimbursement Landscape ... (Photo - http://photos.prnewswire.com/prnh/20140828/140879 ) ... Landscape Poland " an essential source of information ... market and provides insights into the demographic, regulatory, ... report provides valuable insights into the trends and ...
(Date:8/28/2014)... Aug. 28, 2014 Tianyin Pharmaceutical Co., ... pharmaceutical company that specializes in patented biopharmaceutical, modernized ... pharmaceutical ingredients (API) today updates the timeline for ... (QLF). The Company is scheduled ... for China Food & Drug Administration,s (CFDA) review ...
(Date:8/28/2014)... 2014 /PRNewswire-iReach/ -- Academy Leadership, an elite leadership training ... published a case study highlighting one manager,s ... . In September and October 2014, Academy Leadership affiliates ... Albuquerque , Indianapolis , Salt Lake City ... http://photos.prnewswire.com/prnh/20140828/140814 Leadership training for ...
Breaking Medicine Technology:Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 2Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 3Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 4Poland & Turkey Pharmaceutical Market worth $15 billion & $21.5 billion Respectively by 2020 5TPI Submits Dataset for GMP Inspection at Qionglai Facility (QLF) 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 2Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 3Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 4Academy Leaders Publishes Case Study on Work with Global Pharmaceutical Company 5
... During Wednesday,s Satellite Symposium,3: The Challenges of ... the,International Society of Heart and Lung Transplantation ... researchers discussed some of,the unique challenges in ... CF., A highlight of the session ...
... to be Presented at the Upcoming ECCMID Conference, ... the,press release published on 9 April, Arpida Ltd. ... the clinical programme with,intravenous iclaprim in complicated Skin ... has been presented at last year,s ICAAC,and IDSA ...
Cached Medicine Technology:Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting 2Lung Transplants in Cystic Fibrosis Patients With Life-Threatening Bacteria Sparks Debate at ISHLT Meeting 3Arpida Provides Further Comments on the Pivotal Phase III Trials 2Arpida Provides Further Comments on the Pivotal Phase III Trials 3Arpida Provides Further Comments on the Pivotal Phase III Trials 4
(Date:8/28/2014)... (PRWEB) August 28, 2014 American adults ... industry on the Internet will now have a simpler ... company. In one click this year, some of the ... http://quotespros.com/life-insurance.html . , The promoted plans that ... Pros finder tool represent popular policies. The term, guaranteed ...
(Date:8/28/2014)... NH As the federal government plans its exit strategy ... to rethink its role in providing health care to veterans, ... of Medicine . , "To simply go on doing more ... that the Veterans Health Administration,s cost and population structure pose ... Institute for Health Policy & Clinical Practice, and David Auerbach, ...
(Date:8/28/2014)... and Ann Arbor, MI (PRWEB) August 28, 2014 ... company and the nation’s leading intraoperative neurophysiology monitoring ("IONM") ... and CFO, to the position of Chief Executive Officer ... CFO, was promoted to President and CFO in 2013 ... growth and success. , “Bill’s efforts and achievements ...
(Date:8/28/2014)... Kirklyn Smith, an office manager for EzCOI.com , ... record by walking 5,000 miles in a single year without ... the thousands of individual stories of TrekDesk treadmill desk users ... more than the others. , Kirklyn has launched a website ... a range of 54,823 steps (presumably on an off day) ...
(Date:8/28/2014)... San Mateo, CA (PRWEB) August 28, 2014 ... announce that the MRI Technology program is re-accredited for ... Registry of Magnetic Resonance Imaging Technologists (ARMRIT). , ... re-accreditation. We are constantly improving our program to make ... There is a lot of interest in MRI field ...
Breaking Medicine News(10 mins):Health News:Best Life Insurance Rates for 2014 Now Promoted at Insurer Website 2Health News:A VA exit strategy 2Health News:Biotronic NeuroNetwork Announces the Promotion of Bill Gecsey to CEO 2Health News:There are many reasons why Americans' exercise levels have declined - Meet an executive that refuses to sit still with his TrekDesk Treadmill Desk even in a sedentary job 2Health News:Gurnick Academy’s MRI Program Is Re-Accredited by ARMRIT for the 5 Years 2
... Medical,Equipment, Inc. (Pink Sheets: SHMM) announced today that ... completed its seventh,staffing agreement and is aggressively filling ... CEO of parent company Southern Home Medical,stated, "This ... has far,exceeded their own expectations in their second ...
... June 26, 2008 -- Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), announced ... candidate in its Beta-catenin Pathway Inhibitor program. This novel compound ... cancer cell death. The Company plans to begin ... is one of the most commonly activated cancer pathways and ...
... Pryor, CEO of Portico,Learning Solutions (Portico), a provider ... Portico,s partnership with FOX,Networks Group (FNG), the umbrella ... Networks, FOX Reality, and the National Geographic,Channel., ... News Corporation businesses,FNG launched a massive effort to ...
... Mandate is Quick to Implement, ROCKLIN, Calif., ... a provider of relay and wireless communications and,professional ... AT&T today announced they would become the,first companies ... a,10-digit numbering system described in the FCC ruling ...
... The International Association for Dental Research (IADR) is presenting ... Lecturer in Periodontology at the School of Dental Sciences ... will be presented at the IADR 86th General Session ... Dr. Preshaw holds a B.D.S. from Newcastle University, a ...
... Va. The International Association for Dental Research ... Diagnostic Sciences (Emeritus) at the School of Dental ... Buffalo, as the 2008,recipient of the Pharmacology/Therapeutics/Toxicology Research ... IADR 86th,General Session & Exhibition in Toronto, ON, ...
Cached Medicine News:Health News:Encore Medical Staffing of Greenville Signs Seventh Staffing Agreement 2Health News:Avalon Pharmaceuticals names lead development candidate in beta-catenin inhibitor program 2Health News:FOX Networks Group in Partnership with Portico Learning Solutions Launches Online Employee Health and Safety Orientation Course for Over 3,300 Employees 2Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 2Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 3Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 4Health News:GoAmerica(R) and AT&T to Demonstrate Fast, Effective 10-Digit Interoperability Between Video Relay Providers 5Health News:Fischman receives Pharmacology/Therapeutics/Toxicology Research Award 2
Kit Nebulizer Small Volume Medication W/Pediatric Mask Mouthpiece 7FT O 2 Tubing...
Nebulizer Adapter Kit 6"...
... Anesthesia and Respiratory Products, ,Westmed designs, ... for Anesthesia and Respiratory professionals. Our mission ... enhance the clinician's ability to deliver quality ... the bottom line. , ,Our web ...
... The Raindrop® medication nebulizer achieves optimum ... MMAD particle size range is 1.04-1.10 µ ... compressor or air outlet., ,As the ... gives healthcare providers the assurance of proven ...
Medicine Products: